Shell Stocks; Reverse Mergers; Acquisitions; Zombies; Greys; & All "Other" Plays

[Potse]

PGUZ(.002)...worth monitoring for possible changes....

An extremely high-risk investment, but I'm still holding my position in PGUZ in case there is an upcoming change/addition to management or some other catalyst that might cause movement in the stock.

The CEO (Daniel Kesonen) passed away on August 4 from cancer (and I believe there was a stroke at some point, based on a social media posting I have seen). I would assume his health had been declining for much of 2017.

Kesonen had mentioned to other shareholders last year about the possibility of issuing an update/news around August/September of 2016. Kesonen seemed to make it clear that PGUZ was still actively involved in the areas of mold treatment and cardiac diagnostics. Obviously that update did not occur, but I did find it somewhat interesting that websites apparently closely associated with PGUZ's technologies had unusual update activity during 2016. For example, websites connected to PGUZ's MoldGuardian product had new images/pictures uploaded to those sites right around the time frame of June-August 2016.

PGUZ's annual filing for Nevada is due in about 2 months. Olof Hildebrand (who I believe is an active lawyer in Europe/Sweden) is the only other officer listed. So it should be interesting to see what happens when the Nevada deadline arrives. I am crossing my fingers that there were contingency plans put in place prior to Kesonen's death, and that Hildebrand or one of Kesonen's business associates will keep the company active in some form (either as a current operating company or a shell vehicle for a reverse merger).

http://www.legacy.com/obituaries/dignitymemorial/obituary.aspx?n=daniel-kesonen&pid=186304034